Melbourne Clinical Trials

The Longevity Study

The study drug is a potential treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

8 nights
1 phone call + 6 visits

ADPKD is the most common genetic cause of kidney disease affecting up to 12 million people globally and accounts for up to 10% of dialysis (is a way to clean your blood if your kidneys are not working properly) patients. ADPKD patients develop large fluid-filled cysts in their kidneys that compress kidney tissue, causing kidney dysfunction and kidney failure in over half of the patients by 50-60 years of age.

The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.

Call us on 1800 243 733 to discuss your eligibility today!


Biological sex Healthy males and females of non-childbearing potential
Age 18 – 65 years old
BMI 18–32 kg/m2
Weight Weigh more than 45kg for females and more than 50kg for males
Medication Not taking any medication
Medical History No significant medical history
Asthma History No history of adult asthma